The impact of progesterone receptor isoforms expression to invasion capacity and SULT1E1 in endometrial cancer cells

Aim: This study aimed to investigate the mechanism by which progesterone receptors (PRs) mediate in metastatic spread of endometrial cancer (EC). Materials and Methods: The expressions of human progesterone receptor isoforms A and B (hPRA and hPRB) in Ishikawa endometrial cancer cells transfected were examined by Western blot. Matrigel invasion assay was performed to illustrate the roles of hPRA and hPRB in EC metastasis.The underlying mechanism of PR regulating invasion was assessed by Western blot and RT-PCR. Results: In this study ,the authors found a significant increased expression of hPRA and hPRB in transfected cells, respectively, whereas hPRB exhibited a slightly decreased expression upon hPRA stimulation. Matrigel invasion assay demonstrated that hPRB decreased cell invasion, and this process could be largely restored by hPRA treatment. Further study of potential mechanism indicated that hPRB upregulated the expression of SULT1E1, which was connected with endometrial oncogenesis, and the suppression of hPRB via hPRA, exerted an inhibitory effect on the expression of SULT1E1. Conclusions: The above data showed that hPRB promoted the expression of SLUT1E1 to inhibite the invasion of EC cells. In contrast, hPRA played an opposite role in attenuating the effects of hPRB on the invasion of Ishikawa cells and the expression of SLUT1E1.

hPRA; hPRB; SULT1E1; Endometrial cancer; Invasion.

[1] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[2] Colombo N., Preti E., Landoni F., Carinelli S., Colombo A., Marini C., et al.: “Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2013, 24, vi33.

[3] Kim J.J., Chapman-Davis E.: “Role of progesterone in endometrial cancer”. Semin. Reprod. Med., 2010, 28, 81.

[4] Adjei A.A., Weinshilboum R.M.: “Catecholestrogen sulfation: possible role in carcinogenesis”. Biochem. Biophys. Res. Commun., 2002, 292, 402.

[5] Falany J.L., Macrina N., Falany C.N: “Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation”. Breast Cancer Res. Treat., 2002, 74, 167.

[6] Amar D., Berger I., Amara N., Tafa G., Meijler M.M., Aharoni A.: “The transition of human estrogen sulfotransferase from generalist to specialist using directed enzyme evolution”. J. Mol. Biol., 2012, 416, 21.

[7] Choi J.Y., Lee K.M., Park S.K., Noh D.Y., Ahn S.H., Chung H.W., et al.: “Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1090.

[8] Falany J.L., Falany C.N.: “Regulation of SULT1E1 expression in Ishikawa adenocarcinoma cells by tibolone”. Steroids, 2006, 71, 880.

[9] Lange C.A., Yee D.: “Progesterone and breast cancer”. Womens Health (Lond.), 2008, 4, 151.

[10] Hennessy B.T., Coleman R.L., Markman M.: “Ovarian cancer”. Lancet, 2009, 374, 1371.

[11] Wang Y., Hanifi-Moghaddam P., Hanekamp E.E., Kloosterboer H.J., Franken P., Veldscholte J., et al.: “Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer”. Clin. Cancer Res., 2009, 15, 5784.

[12] Mokhtar N.M., Cheng C.W., Cook E., Bielby H., Smith S.K., Charnock-Jones D.S.: “Progestin regulates chemokine (C-X-C motif) ligand 14 transcript level in human endometrium”. Mol. Hum. Reprod., 2010, 16, 170.

[13] Bruner-Tran K.L., Eisenberg E., Yeaman G.R., Anderson TA, McBean J, Osteen KG:” Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice”. J. Clin. Endocrinol. Metab., 2002, 87, 4782.

[14] Ace C.I., Okulicz W.C.: “Microarray profiling of progesterone-regulated endometrial genes during the rhesus monkey secretory phase”. Reprod. Biol. Endocrinol., 2004, 2, 54.

[15] Neubauer N.L., Ward E.C., Patel P., Lu Z., Lee I., Blok L.J., et al.: “Progesterone receptor-B induction of BIRC3 protects endometrial cancer cells from AP1-59-mediated apoptosis”. Horm. Cancer, 2011, 2, 170.

[16] Hopp T.A., Weiss H.L, Hilsenbeck SG, Cui Y, Allred DC, Horwitz KB, et al.: “Breast cancer patients with progesterone receptor PR-Arich tumors have poorer disease-free survival rates”. Clin. Cancer Res., 2004, 10, 2751.

[17] Logan M, Hawkins SM: “Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies”. Clin Sci (Lond.), 2015, 128, 153.

[18] Xu Y., Liu X., Guo F., Ning Y., Zhi X., Wang X., et al.: “Effect of estrogen sulfation by SULT1E1 and PAPSS on the development of estrogen- dependent cancers”. Cancer Sci., 2012, 103, 1000.

[19] Hirata H., Hinoda Y., Okayama N., Suehiro Y., Kawamoto K., Kikuno N., et al.: “CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility”. Cancer, 2008, 112, 1964.